And for those naturally wanting to understand whether it's worth carrying this facility, suggest you also take a gander at this article, headlined "Weighing The Benefits Of In-House Manufacturing For Cell And Gene Therapies": https://www.cellandgene.com/doc/weighing-the-benefits-of-in-house-manufacturing-for-cell-and-gene-therapies-0001
DYOR.
Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy, page-347
-
- There are more pages in this discussion • 160 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.003(5.43%) |
Mkt cap ! $349.6M | |||
| Open | High | Low | Value | Volume |
| 4.7¢ | 4.9¢ | 4.6¢ | $716.0K | 15.11M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 4643641 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 3069108 | 17 |
View Market Depth
| Last trade - 13.32pm 11/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |